<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">30137772</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK519488</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-30611">Trihexyphenidyl</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Jilani</LastName><ForeName>Talha N.</ForeName><Initials>TN</Initials><AffiliationInfo><Affiliation>HCA Healthcare Sunrise Health Graduate Medical Education Program</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabir</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Rawalpindi Medical University</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mery Fitzgerald Hospital</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Trihexyphenidyl works as an anticholinergic and is used for the treatment of tremors, spasms, stiffness, and weak muscle control seen in patients with Parkinson disease. It can also be used to prevent or treat similar muscular conditions, which are caused by certain central nervous system (CNS) drugs such as fluphenazine, haloperidol, chlorpromazine. It was approved for the management of all types of parkinsonism (idiopathic, postencephalitic, and arteriosclerotic) in June 2003 by the FDA. This activity outlines the indications, mechanism of action, methods of administration, important adverse effects, contraindications, toxicity, and monitoring, of trihexyphenidyl so providers can direct patient therapy as indicated as part of the interprofessional team.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s2">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s3">Mechanism of Action</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s4">Administration</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s5">Adverse Effects</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s6">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s7">Monitoring</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s8">Toxicity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s9">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s10">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-30611" sec="article-30611.s11">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>2</Month><Day>27</Day></ContributionDate><ReferenceList><Reference><Citation>McInnis M, Petursson H. Withdrawal of trihexyphenidyl. Acta Psychiatr Scand. 1985 Mar;71(3):297-303.</Citation><ArticleIdList><ArticleId IdType="pubmed">3984771</ArticleId></ArticleIdList></Reference><Reference><Citation>Brocks DR. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999 May-Aug;2(2):39-46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10952768</ArticleId></ArticleIdList></Reference><Reference><Citation>Giachetti A, Giraldo E, Ladinsky H, Montagna E. Binding and functional profiles of the selective M1 muscarinic receptor antagonists trihexyphenidyl and dicyclomine. Br J Pharmacol. 1986 Sep;89(1):83-90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1917044</ArticleId><ArticleId IdType="pubmed">2432979</ArticleId></ArticleIdList></Reference><Reference><Citation>Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000 Mar;25(3):515-32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10774721</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs AM, Fan X, Donsante C, Jinnah HA, Hess EJ. Trihexyphenidyl rescues the deficit in dopamine neurotransmission in a mouse model of DYT1 dystonia. Neurobiol Dis. 2019 May;125:115-122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6863078</ArticleId><ArticleId IdType="pubmed">30707939</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs and Lactation Database (LactMed) [Internet] National Library of Medicine (US); Bethesda (MD): 2006. Trihexyphenidyl.</Citation><ArticleIdList><ArticleId IdType="pubmed">30000731</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijer IA.  VPS13D Movement Disorder. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet] University of Washington, Seattle; Seattle (WA): 2019. Feb 21, </Citation><ArticleIdList><ArticleId IdType="pubmed">30789691</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey AR, Baker LB, Reddihough DS, Scheinberg A, Williams K. Trihexyphenidyl for dystonia in cerebral palsy. Cochrane Database Syst Rev. 2018 May 15;5:CD012430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6494536</ArticleId><ArticleId IdType="pubmed">29763510</ArticleId></ArticleIdList></Reference><Reference><Citation>Begbie F, Walker G, Kubba H, Sabharwal A. Acute colonic pseudo-obstruction in a child taking trihexyphenidyl for drooling: Prescribers beware. Int J Pediatr Otorhinolaryngol. 2015 Jun;79(6):932-934.</Citation><ArticleIdList><ArticleId IdType="pubmed">25912627</ArticleId></ArticleIdList></Reference><Reference><Citation>Robottom BJ, Reich SG. Exposure to high dosage trihexyphenidyl during pregnancy for treatment of generalized dystonia: case report and literature review. Neurologist. 2011 Nov;17(6):340-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">22045287</ArticleId></ArticleIdList></Reference><Reference><Citation>Petković S, Durendić-Brenesel M, Dolai M, Samojlik I. Fatal intoxication because of trihexyphenidyl. J Forensic Sci. 2011 Sep;56(5):1383-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21644988</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30137772</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
